Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Shares of Immuneering Corporation IMRX were up 5.1% yesterday after the company announced the dosing of the first patient in a pivotal phase III study evaluating its lead product candidate, atebimetinib (IMM-1-104), in combination with modified gemcitabine/nab-paclitaxel (mGnP) for the first-line treatment of metastatic pancreatic cancer.

The global phase III MAPKeeper 301 study will evaluate the safety and efficacy of atebimetinib, a dual MEK inhibitor plus mGnP, in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who have received no prior systemic anti-cancer therapy.

In the MAPKeeper 301 study, patients will be randomized to receive either atebimetinib (320 mg once daily) in combination with mGnP or standard-of-care GnP alone.

The primary endpoint of the study is overall survival (OS), while key secondary endpoints include progression-free survival, overall response rate, disease control rate, safety and tolerability and quality of life.

Top-line data from the MAPKeeper 301 study is expected to be announced in mid-2028.

IMRX Price Performance

Year to date, shares of Immuneering have declined 37.4% compared with the industry’s decrease of 3.3%.Zacks Investment Research

Image Source: Zacks Investment Research

IMRX's Updates on Atebimetinib Development

In January 2026, the company reported positive updated OS and safety data from the phase IIa study arm evaluating atebimetinib plus mGnP for treating first-line pancreatic cancer.

Data from the study showed that the combination of atebimetinib plus mGnP led to a 64% OS at 12 months compared to 35% for the standard of care in the given patient population.

The company is also developing atebimetinib as a monotherapy in third-line pancreatic cancer.

Beyond pancreatic cancer, Immuneering is evaluating atebimetinib in combination with Regeneron's REGN anti-PD-1 therapy, Libtayo (cemiplimab), in a phase II study in patients with first-line RAS-mutant non-small-cell lung cancer (NSCLC). Dosing in the study is expected to begin in the second half of 2026.

In February 2025, Immuneering entered into a collaboration with Regeneron to evaluate atebimetinib in combination with Libtayo for treating NSCLC.

Per this agreement, Immuneering will fund the planned studies while REGN will supply Libtayo, which is approved for multiple cancer indications.

Immuneering Corporation PriceImmuneering Corporation Price

Immuneering Corporation price | Immuneering Corporation Quote

IMRX's Zack Rank & Stocks to Consider

Immuneering currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Liquidia Corporation LQDA and Immunocore IMCR, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Story Continues

Over the past 60 days, estimates for Liquidia’s 2026 EPS have increased to $2.97 from $1.50. Over the same period, EPS estimates for 2027 have risen to $4.81 from $2.91. LQDA shares have surged 107.7% year to date.

Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.

Over the past 60 days, estimates for Immunocore’s 2026 bottom line have improved from a loss of 88 cents per share to earnings of 6 cents. Over the same period, EPS estimates for 2027 have risen from 24 cents to 87 cents. IMCR shares have lost 17.5% year to date.

Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 46.66%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report

Liquidia Corporation (LQDA) : Free Stock Analysis Report

Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report

Immuneering Corporation (IMRX) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

This article first appeared on GuruFocus.

Parabilis Medicines is coming to market with serious momentum behind it. The clinical-stage cancer drug developer raised nearly $745 million through an upsized US initial public offering and a private placement, after pricing its IPO above the marketed range. The Cambridge, Massachusetts-based company sold 33.5 million shares at $20 each, raising $670 million from the IPO alone. That price came above the earlier $17 to $19 range, even after the company had already increased the offering size to 33.3 million shares earlier Tuesday.

Warning! GuruFocus has detected 3 Warning Signs with REGN. Is REGN fairly valued? Test your thesis with our free DCF calculator.

Regeneron Pharmaceuticals (NASDAQ:REGN) also stepped in with fresh backing, agreeing to buy 4.17 million Parabilis shares at $18 each, adding nearly $75 million through a private placement. That investment follows the research collaboration Regeneron announced with Parabilis in May, which included a $50 million upfront payment and a pledge to buy stock in Parabilis' next equity offering. At the IPO price, Parabilis is valued at about $2.4 billion based on outstanding shares listed in the filing. Demand appeared strong before the earlier upsize, with the IPO reportedly attracting orders for about 10 times the available shares.

The big question now is whether investor excitement can carry into public trading. Parabilis, founded in 2015, is developing therapies for various cancers and rare tumors, and plans to use the proceeds to move zolucatetide, its most advanced drug candidate, into later-stage trials. The company remains deeply loss-making, with a net loss of $145.9 million for the year ended in 2025, compared with $117.9 million the year before, while cash and cash equivalents fell to $27.7 million from $47.3 million. Leerink Partners, Bank of America, Evercore, Guggenheim Securities and LifeSci Capital are leading the offering, with shares expected to trade on the Nasdaq Global Market under the symbol PBLS.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

[Wooden blocks with the word IPO and virtual stock graph. Initial Public Offering or stock launch concept.] fadfebrian

Parabilis Medicines (PBLS [https://seekingalpha.com/symbol/PBLS]) climbed more than 45% in its first trading session on Wednesday after the cancer drug developer backed by a recent research deal with Regeneron (REGN [https://seekingalpha.com/symbol/REGN]) made its public debut following a record-setting IPO among biotechs. [https://seekingalpha.com/news/4602043-parabilis-medicines-prices-upsized-ipo-at-20-per-share]

The company priced the upsized offering of roughly 33.3M shares at $20 each late Tuesday, valuing it at $2.4B and expecting $670M in gross proceeds, excluding roughly $75M sought from a concurrent private placement to Regeneron (REGN [https://seekingalpha.com/symbol/REGN]).

The offering surpassed Moderna’s (MRNA [https://seekingalpha.com/symbol/MRNA]) then-record $604M IPO haul in 2018 and $625M generated by obesity drug developer Kailera Therapeutics (KLRA [https://seekingalpha.com/symbol/KLRA]) from its market debut in April.

Shares of the Cambridge, Massachusetts-based company opened at $33.35 at about 12:40 pm ET, indicating roughly a 67% gain from the IPO price before reaching $28.81 at about 1:00 pm ET, implying nearly a 44% rise.

Founded in July 2015 as FOG Pharmaceuticals, Parabilis (PBLS [https://seekingalpha.com/symbol/PBLS]) is a clinical-stage developer of a peptide-based treatment class called "Helicons.”

Its Helicon drug discovery platform is based on technology licensed from serial biotech entrepreneur Gregory Verdine, whose early research paved the way for Revolution Medicines’ (RVMD [https://seekingalpha.com/symbol/RVMD]) breakthrough pancreatic cancer therapy, daraxonrasib.

MORE ON REGENERON PHARMACEUTICALS, PARABILIS MEDICINES, INC.

* Regeneron Pharmaceuticals, Inc. (REGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript [https://seekingalpha.com/article/4913022-regeneron-pharmaceuticals-inc-regn-presents-at-goldman-sachs-47th-annual-global-healthcare]
* Regeneron: 'Buy' Revenue Growth And Two Extensive Drug Development Opportunities [https://seekingalpha.com/article/4912777-regeneron-buy-revenue-growth-and-two-extensive-drug-development-opportunities]
* Parabilis Medicines Starts IPO On Promising Cancer Therapy Trials [https://seekingalpha.com/article/4908000-parabilis-medicines-starts-ipo-on-promising-cancer-therapy-trials]
* Parabilis Medicines prices upsized IPO at $20 per share [https://seekingalpha.com/news/4602043-parabilis-medicines-prices-upsized-ipo-at-20-per-share]
* Parabilis upsizes IPO seeking to raise more than $600M [https://seekingalpha.com/news/4601898-parabilis-upsizes-ipo-seeking-raise-more-than-600m]

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

ANI Pharmaceuticals ANIP is executing a clear pivot toward higher-margin specialty revenues, led by Purified Cortrophin Gel. That momentum is now showing up in earnings power and a higher 2026 outlook.

The debate is whether that upside is strong enough to offset two real risks: intensifying competition in key markets and meaningful customer concentration. That tradeoff frames the rest of the setup.

ANIP’s Setup: Growth Engine vs. Risk Factors

Cortrophin Gel has become the company’s primary growth engine, driving the Rare Disease franchise and pushing the mix toward specialty therapies. In 2025, Cortrophin delivered $347.8 million in revenue, up about 76% year over year, and management expects that strength to continue in 2026 with sales guidance of $540-$575 million. The company is also investing behind adoption, including a dedicated ~90-person sales force focused on acute gouty arthritis flares and a prefilled syringe formulation that has already become the majority of new patient starts.

The key offsets are competition and concentration. In retina, the Iluvien franchise faces entrenched alternatives from larger players. AbbVie ABBV markets Ozurdex, which competes across diabetic macular edema and chronic non-infectious uveitis affecting the posterior segment, while Regeneron Pharmaceuticals REGN remains a major force in diabetic macular edema through Eylea and Eylea HD. On the distribution side, three wholesale customers represented 53% of 2025 net revenue and 64% of accounts receivable, which can amplify pricing pressure if purchasing leverage increases.

ANI Pharmaceuticals’ 2026 Guidance

After the strong first quarter, ANI raised its full-year 2026 total net revenue outlook by $25 million to $1.08-$1.14 billion. It also lifted adjusted EBITDA guidance by $10 million to $285-$300 million and raised adjusted earnings per share to $9.19-$9.69 from $8.83-$9.34.

Importantly, the company reaffirmed product-level expectations for both key branded drivers. Cortrophin Gel remained guided to $540-$575 million, and Iluvien was reaffirmed at $78-$83 million, which implies a return to growth versus 2025.

Management tied the higher full-year outlook to two drivers: stronger-than-expected Generics performance exiting the first quarter and improved visibility into upcoming launches for the remainder of 2026. That combination matters because it supports the idea that the guidance raise was not solely a one-quarter timing benefit.

ANIP’s Q1 2026 Performance as a Validation Point

First-quarter 2026 results provided a clean validation point. Adjusted earnings per share came in at $2.05, up nearly 21% year over year and well ahead of the $1.28 consensus estimate. Revenue was $237.5 million, up 20.5% year over year and above the $205.4 million consensus estimate.

Story Continues

Two items stood out in the quarter. First, Cortrophin maintained strong momentum, with net revenue rising 42% to $75.1 million. Second, ANI benefited from a newly monetized intellectual property licensing arrangement that added meaningful royalties and other revenue.

Rare Disease and Brands net revenue grew 36% to $128.2 million, supported by both Cortrophin and Iluvien, with Iluvien sales up 19.5% to $19.3 million. The mix also shifted as the company recorded $21.5 million in brand royalties and other revenues tied to the Harmony Biosciences HRMY licensing agreement, including a $15 million upfront fee and early royalty income.

ANI Pharmaceuticals, Inc. PriceANI Pharmaceuticals, Inc. Price

ANI Pharmaceuticals, Inc. price | ANI Pharmaceuticals, Inc. Quote

ANI Pharmaceuticals’ Cash, Leverage and Flexibility

ANI ended March 31, 2026 with $311.2 million in unrestricted cash and cash equivalents, up from $285.6 million at the end of 2025. Operating cash flow was $58.4 million in the quarter, reflecting the improved earnings profile and working-capital dynamics.

Debt remains meaningful but structured in a way management frames as manageable. As of quarter-end, ANI reported $625 million in principal value of outstanding debt, including senior convertible notes and a term loan. Management cited gross leverage of 2.6x and net leverage of 1.3x based on trailing 12-month adjusted non-GAAP EBITDA of $242 million.

That balance sheet profile supports continued investment in the Rare Disease buildout and leaves room for potential inorganic opportunities, which the company has highlighted as part of its broader growth approach.

ANIP’s Share Repurchase Program and Capital Allocation

Alongside the guidance raise, ANI authorized a new $100 million share repurchase program running through May 2029. The timing is notable because it adds an additional capital allocation lever while the company is still investing in commercial infrastructure and maintaining a stated focus on business development.

In practice, the authorization gives management flexibility to respond to valuation and cash flow conditions over multiple years rather than forcing a near-term pace. It also signals confidence in the durability of the earnings step-up implied by the updated 2026 outlook.

ANI Pharmaceuticals’ Valuation Context and Price Target Logic

At roughly 9.75x forward twelve-month earnings, ANIP trades well below the Zacks sub-industry multiple of 41.94x, the Zacks sector multiple of 20.32x, and the S&P 500 multiple of 21.43x. Over the past five years, the stock’s forward earnings multiple has ranged from 7.40x to 61.11x, with a median of 15.69x, placing today’s level closer to the low end of its own history.

The price target framework is also explicitly multiple-driven. The $85 target reflects 10.21x forward twelve-month earnings, which sits modestly above the current forward multiple. From here, the valuation looks “cheap” if execution sustains the Cortrophin trajectory, the retina franchise returns to growth as guided, and the generics cadence supports the raised outlook. The multiple can look “deserved” if competitive intensity and customer concentration pressure limit pricing power or slow the recovery path embedded in Iluvien expectations.

ANIP’s Zacks Rank

ANI Pharmaceuticals currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report

AbbVie Inc. (ABBV) : Free Stock Analysis Report

ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report

Harmony Biosciences Holdings, Inc. (HRMY) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

ANI Pharmaceuticals ANIP is leaning harder into its Rare Disease franchise as growth increasingly concentrates around Purified Cortrophin Gel. The next step is a sharper commercial push into acute gouty arthritis flares, which management is treating as a meaningful new demand pocket.

At the same time, the company is working to restore momentum in its retina franchise after a 2025 setback tied to market access. The setup creates a near-term spend cycle, but also clearer checkpoints investors can follow through 2026.

ANIP’s New Demand Pocket: Acute Gouty Arthritis Flares

The commercial expansion into acute gouty arthritis flares is being positioned as an emerging growth initiative for Cortrophin. The rationale is straightforward. Management sees a large, relatively untapped patient population and believes the current penetration level leaves room for sustained growth.

“Targeted execution” here is less about broad-based promotion and more about building a repeatable specialty playbook. The strategy emphasizes focused coverage and tighter field activity around the acute flare opportunity, with execution designed to translate interest into consistent starts rather than one-off wins.

ANI Pharmaceuticals’ Sales Force Buildout and Near-Term Spend

To support the acute gout initiative, ANI is deploying a dedicated sales force of about 90 people. That planned buildout matters for investors because it creates a visible near-term investment cycle in operating expenses.

The early signs of that spending already showed up in first-quarter 2026 trends. Adjusted selling, general and administrative expenses rose 12% year over year to $71.4 million, driven in part by initial marketing and recruitment spending tied to the acute gout commercial buildout. Investors should frame the cost increase as the front end of a growth effort, with expense momentum tracking headcount ramp, training, and field execution as the organization scales into the targeted acute gout channel.

ANIP’s Prefilled Syringe: A Practical Adoption Lever

ANI also has a practical adoption lever in the form of a prefilled syringe formulation for Cortrophin. The key point is usability. Management highlights improved ease of use as a factor that can reduce friction around starts and support wider uptake in the field.

Importantly, the uptake commentary is already tangible. The prefilled syringe has gained rapid traction and is cited as accounting for a majority of new patient starts. That framing keeps the focus on adoption mechanics, where a simpler format can reinforce the impact of a larger commercial footprint.

Story Continues

ANI Pharmaceuticals, Inc. PriceANI Pharmaceuticals, Inc. Price

ANI Pharmaceuticals, Inc. price | ANI Pharmaceuticals, Inc. Quote

ANI Pharmaceuticals’ Competitive Reality in ACTH Therapies

Competition is not theoretical in ACTH therapies. The primary competitor named is Acthar Gel, marketed by Keenova Therapeutics, and the market dynamic described is notable because both products are seeing momentum in sales growth.

For ANIP shareholders, that sets up a watch list centered on positioning and access dynamics. If both brands are expanding, the slope of growth can hinge on how consistently ANI converts targeted demand pockets, how effectively it supports access, and how competition influences share capture over time. Separately, competition across ophthalmology is also relevant to the broader story, where AbbVie ABBV and Regeneron Pharmaceuticals REGN are cited as key rivals through products used in overlapping markets.

ANIP’s Second Growth Vector From the Retina Franchise

ANI’s retina franchise is framed as a second growth vector, with Iluvien and Yutiq helping diversify revenue and reduce reliance on Cortrophin. In 2025, the combined Iluvien/Yutiq contribution was $74.9 million, though performance was pressured by market access challenges, including funding constraints affecting patient assistance programs for Medicare beneficiaries.

Management characterized 2025 as a “reset year,” and the response included consolidating Iluvien and Yutiq into a unified Iluvien brand promoted across diabetic macular edema and chronic non-infectious uveitis affecting the posterior segment of the eye. The intention is to streamline promotion and support recovery as access conditions normalize.

ANI Pharmaceuticals’ 2026 Milestones to Watch

The 2026 setup includes several measurable markers. For Iluvien, sales are expected to recover with guidance of $78-$83 million, implying 4%-11% year-over-year growth. On the Generics side, management remains on track for a steady cadence of 10-15 new launches in 2026, reinforcing the segment’s role as a cash-flow foundation even if it is no longer the primary growth driver.

Investors also have discrete milestone checkpoints tied to the Harmony Biosciences HRMY licensing agreement. ANI received a $15 million upfront license fee and expects an additional $10 million in development milestones to be achieved in the second and third quarters of 2026. Taken together, Iluvien’s guided recovery range, the generics launch cadence, and the Harmony milestone timing give ANIP holders a practical scorecard for tracking execution as the Cortrophin acute gout push scales through 2026.

ANIP’s Zacks Rank

ANI Pharmaceuticals currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report

AbbVie Inc. (ABBV) : Free Stock Analysis Report

ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report

Harmony Biosciences Holdings, Inc. (HRMY) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

ANI Pharmaceuticals ANIP is reshaping its growth profile. In 2025, revenue surged on the back of a rare disease franchise that is becoming the company’s defining investment narrative. The key is Purified Cortrophin Gel, an ACTH-based injection that is increasingly central to both top-line expansion and the margin mix.

With 2026 guidance calling for rare disease to become the majority of sales, the next question for investors is what has to keep working for Cortrophin to deliver at scale.

ANIP’s Rare Disease Shift Is Now the Story

ANIP’s revenue momentum is increasingly skewed toward its Rare Disease and Brands segment, reflecting a portfolio tilt toward higher-margin specialty therapies. In fiscal 2025, total revenue was $883.4 million, up 43.8% year over year. Rare Disease and Brands contributed $484.0 million, or 54.8% of total revenue, versus $399.4 million, or 45.2%, from Generics and Other.

Within Rare Disease and Brands, Cortrophin Gel generated $347.8 million in 2025 revenue. The retina franchise Iluvien/Yutiq added $74.9 million, but Cortrophin remained the anchor product. This mix matters because it signals a shift in the durability of growth: performance is being driven less by a broad basket of products and more by a specialty platform with clearer strategic focus.

ANI Pharmaceuticals’ Cortrophin Growth Drivers in 2025

Cortrophin delivered nearly $348 million in 2025 revenue, up about 76% year over year. That increase was a major contributor to the company’s roughly 44% total revenue growth in 2025, reinforcing how tightly overall expansion is now tied to the rare disease franchise.

Rare disease revenue grew more than 80% year over year, underscoring Cortrophin’s outsized role in the model. The result is a growth engine that is not only larger, but also increasingly central to how ANIP is building its commercial strategy around specialty therapies.

ANIP’s 2026 Outlook for Cortrophin Sales

Management guided to 2026 Cortrophin Gel net revenue of $540 million to $575 million. That range sits inside a broader 2026 total net revenue outlook that was raised after the first quarter to $1.08 billion to $1.14 billion.

Mix expectations are just as important as the headline growth. Rare disease is expected to account for the majority of 2026 sales, roughly 60% by management’s framing. Hitting the midpoint of Cortrophin guidance implies that demand continues to broaden across specialties, access remains workable through payer dynamics, and the commercial buildout translates into incremental patient starts, especially in targeted indications such as acute gouty arthritis flares.

Story Continues

ANI Pharmaceuticals, Inc. PriceANI Pharmaceuticals, Inc. Price

ANI Pharmaceuticals, Inc. price | ANI Pharmaceuticals, Inc. Quote

ANI Pharmaceuticals’ Adoption Catalysts Across Specialties

A key part of the growth narrative is under-penetration in the addressable market, with adoption expanding across rheumatology, nephrology, and pulmonology. ANIP is pairing that demand opportunity with targeted commercial execution designed to translate interest into consistent prescribing behavior.

One centerpiece is a planned dedicated ~90-person sales force buildout focused on acute gouty arthritis flares, which management describes as a large and relatively untapped patient population. This is a specific go-to-market decision that aims to turn a narrower specialty footprint into broader utilization while keeping the strategy anchored in rare disease.

Product experience is also part of the adoption story. The prefilled syringe formulation has improved ease of use and has already gained rapid traction, accounting for a majority of new patient starts. In specialty markets, that kind of friction reduction can matter, particularly when the goal is to accelerate uptake across multiple physician channels.

ANIP’s Q1 2026 Check-In and What It Signals

First-quarter 2026 results extended the Cortrophin momentum, with net revenues rising 42% year over year to $75.1 million. Rare Disease and Brands revenue grew 36% to $128.2 million, supported by both Cortrophin and Iluvien contributions.

Management emphasized that Cortrophin’s quarter reflected seasonality tied to insurance re-verifications. The process took longer early in the quarter due to higher patient volume at physician offices. Weather-related office closures in some regions also contributed.

For investors, the takeaway is to be careful about extrapolating a single quarter’s cadence into a full-year run rate. The quarter still showed strong year-over-year growth, but the commentary highlights how administrative timing and access mechanics can influence quarterly variability even in an expanding franchise.

ANI Pharmaceuticals’ Key Risks to Monitor in Rare Disease

Competitive pressure is building in the rare disease space, and Cortrophin’s primary competitor is Acthar Gel, marketed by Keenova Therapeutics. Acthar is described as experiencing similar momentum in sales growth, keeping competitive dynamics relevant as ANIP expands in targeted markets.

More broadly, competing with larger pharmaceutical companies can shape pricing, access, and positioning over time. In ophthalmology, AbbVie ABBV competes through Ozurdex, while Regeneron Pharmaceuticals REGN is a major presence with Eylea and Eylea HD in diabetic macular edema. These companies have scale and entrenched commercial footprints, which can raise the bar for differentiated execution in specialized markets.

ANIP’s Zacks Rank

ANI Pharmaceuticals currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report

AbbVie Inc. (ABBV) : Free Stock Analysis Report

ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Parabilis Medicines priced its initial public offering at $20 per share on Tuesday, raising $670 million in what Fierce Biotech called the largest IPO in biotech history.

A total of 33.5 million shares were sold in the offering, with trading on the Nasdaq Global Select Market under the ticker symbol "PBLS" set to begin Wednesday. The offering priced above the $17-to-$19 range Parabilis had marketed earlier this week, the company said. Underwriters also hold a 30-day option to purchase an additional 5,025,000 shares at the IPO price, which could add roughly $100 million to the total raised.

In a concurrent private placement tied to the offering, Regeneron Pharmaceuticals purchased 4.17 million shares priced at $18 apiece, contributing roughly $75 million to the total. The share purchase stems from a partnership Bloomberg traced to an agreement reached between the two firms in May. Combined, the IPO and private placement raise nearly $745 million.

Parabilis, formerly known as Fog Pharmaceuticals, was co-founded in 2015 and develops a drug class it calls helicon peptides, which are engineered to bind protein targets that have been difficult to address with conventional medicines, the company said. Its pipeline is focused on cancers and rare tumors, according to Reuters.

To date, more than 150 patients have received doses of zolucatetide, the company's leading candidate, which is currently in trials spanning multiple solid tumor types, Reuters reported. According to Fierce Biotech, the company has designated $150 million for a push toward a phase 3 trial of zolucatetide in desmoid tumors — rare noncancerous growths of connective tissue — while an additional $120 million will fund ongoing phase 1 work across other tumor indications.

Until now, obesity drug developer Kailera Therapeutics held the record for the largest biotech IPO after pulling in $625 million in April, a mark Parabilis has now eclipsed, according to Fierce Biotech. Based on outstanding shares in its filing, the company's valuation comes to roughly $2.4 billion at the $20 offering price.

The underwriting syndicate includes Leerink Partners, BofA Securities, Evercore ISI, Guggenheim Securities, and LifeSci Capital, the company said. The IPO is expected to close on or about June 11, 2026.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

(RTTNews) - Sensorion SA (ALSEN.PA), a biotechnology company, on Wednesday announced the selection of SENS-601 for treating GJB2-related hearing loss as the company's lead program, and the simultaneous discontinuation of the Audiogene trial evaluating SENS-501 in the treatment of OTOF-related hearing loss.

Following the announcement, shares fell over 15% on Wednesday.

GJB2 mutations are the most common genetic causes of congenital deafness, responsible for about 50% of autosomal recessive non-syndromic hearing loss cases.

SENS-601 (GJB2-GT) is an AAV-based gene therapy developed to treat GJB2-associated hearing loss. The drug has the potential to treat pediatric congenital deafness, progressive hearing loss in children, and early onset of presbycusis in adults.

The advancement of SENS-601 as the company's lead program was accompanied by applications to initiate the Hearconnex clinical trials in Canada and France, with a Fast Track designation granted by the French National Agency for Medicines and Health Products Safety (ANSM). The Hearconnex trials will evaluate safety, tolerability, and efficacy of the intra-cochlear administration of SENS-601 in pediatric patients.

The SENS-501 gene therapy was developed to target the otoferlin gene (OTOF), which effects transmission of auditory signals between the hair cells of the inner ear and the auditory nerve. Mutations in the OTOF gene can cause severe to profound hearing loss. The therapy was being assessed in the Phase 1/2 Audiogene trial, which showed positive results prior to discontinuation.

However, Otarmeni, a gene therapy from Regeneron Pharmaceuticals Inc., received FDA approval in April for the treatment of OTOF-related hearing loss. The company attributed the termination of the Audiogene program for SENS-501 to the availability of the Otarmeni therapy, stating that resources would be better directed toward development of SENS-601 in treating GJB2-related hearing loss, which is an affliction with no currently approved therapies.

Sensorion plans to submit an investigational new drug (IND) application for SENS-601 to the U.S. FDA and in Australia by the end of 2026.

ALSEN.PA is currently trading on the Paris Stock Exchange at EUR 0.31, down 15.52%.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the Invesco Biotechnology & Genome ETF (PBE), a passively managed exchange traded fund launched on June 23, 2005.

Passively managed ETFs are becoming increasingly popular with institutional as well as retail investors due to their low cost, transparency, flexibility and tax efficiency. They are excellent vehicles for long term investors.

Sector ETFs are also funds of convenience, offering many ways to gain low risk and diversified exposure to a broad group of companies in particular sectors. Healthcare - Biotech is one of the 16 broad Zacks sectors within the Zacks Industry classification. It is currently ranked 9, placing it in bottom 44%.

Index Details

The fund is sponsored by Invesco. It has amassed assets over $260.13 million, making it one of the average sized ETFs attempting to match the performance of the Healthcare - Biotech segment of the equity market. PBE seeks to match the performance of the Dynamic Biotechnology & Genome Intellidex Index before fees and expenses.

The Dynamic Biotech & Genome Intellidex Index seeks to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value.

Costs

When considering an ETF's total return, expense ratios are an important factor, and cheaper funds can significantly outperform their more expensive counterparts in the long term if all other factors remain equal.

Annual operating expenses for this ETF are 0.58%, making it on par with most peer products in the space.

It has a 12-month trailing dividend yield of 1.03%.

Sector Exposure and Top Holdings

While ETFs offer diversified exposure, which minimizes single stock risk, a deep look into a fund's holdings is a valuable exercise. And, most ETFs are very transparent products that disclose their holdings on a daily basis.

This ETF has heaviest allocation in the Healthcare sector -- about 100% of the portfolio.

Looking at individual holdings, United Therapeutics Corp (UTHR) accounts for about 6.33% of total assets, followed by Illumina Inc (ILMN) and Regeneron Pharmaceuticals Inc (REGN).

The top 10 holdings account for about 48.13% of total assets under management.

Performance and Risk

Year-to-date, the Invesco Biotechnology & Genome ETF has added about 2.65% so far, and is up roughly 30.09% over the last 12 months (as of 06/10/2026). PBE has traded between $63.376 and $85.733 in this past 52-week period.

Story Continues

The ETF has a beta of 0.72 and standard deviation of 19.77% for the trailing three-year period, making it a high risk choice in the space. With about 33 holdings, it has more concentrated exposure than peers.

Alternatives

Invesco Biotechnology & Genome ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. Thus, PBE is a good option for those seeking exposure to the Health Care ETFs area of the market. Investors might also want to consider some other ETF options in the space.

iShares Biotechnology ETF (IBB) tracks Nasdaq Biotechnology Index and the State Street SPDR S&P Biotech ETF (XBI) tracks S&P Biotechnology Select Industry Index. iShares Biotechnology ETF has $7.87 billion in assets, State Street SPDR S&P Biotech ETF has $8.01 billion. IBB has an expense ratio of 0.44%, and XBI charges 0.35%.

Bottom Line

To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Invesco Biotechnology & Genome ETF (PBE): ETF Research Reports

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

[IPO and Stock Market Analysis] bymuratdeniz

* Parabilis Medicines (PBLS [https://seekingalpha.com/symbol/PBLS]) priced [https://seekingalpha.com/pr/20546168-parabilis-medicines-announces-pricing-of-upsized-initial-public-offering] its upsized IPO of 33.3M shares at $20 per share. The underwriters have a 30-day option to buy an additional ~5M shares . 
* The common stock is expected to begin trading on the Nasdaq on June 10, 2026 under the ticker symbol “PBLS”. 
* The offering is expected to close on or about June 11, 2026.
* Alongside the shares offered in the IPO, Parabilis agreed to sell 4.17 million shares of common stock to Regeneron Pharmaceuticals (REGN [https://seekingalpha.com/symbol/REGN]) in a concurrent private placement at $18 per share, representing a 10% discount to the IPO price of $20.00 per share.
* Parabilis expects to raise ~$670M in gross proceeds from its IPO, and $75M from the concurrent private placement with Regeneron (REGN [https://seekingalpha.com/symbol/REGN])

MORE ON PARABILIS MEDICINES, INC.

* Parabilis Medicines Starts IPO On Promising Cancer Therapy Trials [https://seekingalpha.com/article/4908000-parabilis-medicines-starts-ipo-on-promising-cancer-therapy-trials]
* Parabilis upsizes IPO seeking to raise more than $600M [https://seekingalpha.com/news/4601898-parabilis-upsizes-ipo-seeking-raise-more-than-600m]
* Regeneron backed Parabilis seeks up to $476M in U.S. IPO [https://seekingalpha.com/news/4600737-regeneron-backed-parabilis-seeks-476m-in-ipo]
* Financial information for Parabilis Medicines, Inc. [https://seekingalpha.com/symbol/PBLS/income-statement]